Approved Jan. 5, Purepac's cefadroxil 500 mg caps will be available soon, the company said. Purepac's parent company, Kalipharma, filed a suit in July seeking a declaratory judgment that Bristol's cefadroxil patent is invalid. Purepac received the second cefadroxil ANDA approval following Zenith's in March 1987. Bristol took Zenith to court for patent infringement and the claim was dropped after a consent order was handed down ("The Pink Sheet" June 1, 1987 "In Brief"). Zenith said it is not marketing cefadroxil.
You may also be interested in...
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.
The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.